Pedro Marques Ramos
Novartis
16 Papers
7 Citations
Pedro Marques Ramos is an academic researcher from Novartis. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 11 publications. Previous affiliations of Pedro Marques Ramos include Friedrich Miescher Institute for Biomedical Research.
Chat about Author
Papers
Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition
Cédric Leroy,Cédric Leroy,Pedro Marques Ramos,Pedro Marques Ramos,Karen Cornille,Debora Bonenfant,Christine Fritsch,Hans Voshol,Mohamed Bentires-Alj +8 more
TL;DR: This study demonstrates that the IGF1R/p110β/AKT/mTOR axis confers resistance to BYL719 in PIK3CA mutant breast cancers, which provides a rationale for the combined targeting of p110α with IGF 1R or p110β in patients with breast tumors harboring Pik3CA mutations.
Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag
Yun Ruei Kao,Jiahao Chen,Swathi Rao Narayanagari,Tihomira I. Todorova,Maria M. Aivalioti,Mariana da Silva Ferreira,Pedro Marques Ramos,Celine Pallaud,Ioannis Mantzaris,Ioannis Mantzaris,Aditi Shastri,Aditi Shastri,James B. Bussel,Amit Verma,Amit Verma,Ulrich Steidl,Britta Will +16 more
TL;DR: It is demonstrated that EP stimulates hematopoiesis at the stem cell level through iron chelation–mediated molecular reprogramming and indicates that labile iron pool–regulated pathways can modulate HSC function.
63
Machine Learning of Bone Marrow Histopathology Identifies Genetic and Clinical Determinants in Patients with MDS
Oscar Brück,Susanna Lallukka-Brück,Helena Hohtari,Aleksandr Ianevski,Freja Ebeling,Panu E. Kovanen,Soili Kytölä,Tero Aittokallio,Tero Aittokallio,Tero Aittokallio,Pedro Marques Ramos,Kimmo Porkka,Satu Mustjoki +12 more
TL;DR: Convolutional neural networks were used to extract morphologic features from 236 MDS, 87 MDS/MPN, and 11 control BM biopsies to highlight the potential of linking deep BM histopathology with genetics and clinical variables and molecular genetics.
The NFIB-ERO1A axis promotes breast cancer metastatic colonization of disseminated tumour cells.
Federica Zilli,Federica Zilli,Pedro Marques Ramos,Pedro Marques Ramos,Priska Auf der Maur,Charly Jehanno,Atul Sethi,Atul Sethi,Atul Sethi,Marie-May Coissieux,Marie-May Coissieux,Tobias Eichlisberger,Loïc Sauteur,Adelin Rouchon,Laura Bonapace,Joana Pinto Couto,Joana Pinto Couto,Joana Pinto Couto,Roland Rad,Roland Rad,Michael Rugaard Jensen,Andrea Banfi,Michael B. Stadler,Michael B. Stadler,Mohamed Bentires-Alj,Mohamed Bentires-Alj +25 more
TL;DR: In this article, an inducible piggyBac transposon mutagenesis screen was used to show that NFIB alone is sufficient to enhance primary mammary tumour growth and lung metastatic colonization.
Short-term administration of JAK2 inhibitors reduces splenomegaly in mouse models of β-thalassemia intermedia and major
Carla Casu,Vania Lo Presti,Paraskevi Rea Oikonomidou,Luca Melchiori,Osheiza Abdulmalik,Pedro Marques Ramos,Stefano Rivella +6 more
TL;DR: Clinical studies in patients affected by myeloproliferative disorders, characterized by activating JAK2 mutations, suggest that JAK1 inhibitors (JAK2i) are an effective treatment for splenomegaly, and therefore could be used as an alternative to splenectomy.